Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Evofem Biosciences, Inc. (NASDAQ: EVFM).

Full DD Report for EVFM

You must become a subscriber to view this report.


Recent News from (NASDAQ: EVFM)

Midday Gainers / Losers (05/07/2018)
Gainers: BLNK +184% . XTLB +92% . NFEC +24% . AGMH +21% . AXON +18% . VVPR +19% . ATHN +16% . GPT +15% . NCMI +15% . TWIN +15% . More news on: Blink Charging Co., XTL Biopharmaceuticals Ltd., NF Energy Saving Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 07 2018 12:47
Evofem Biosciences Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health...
Source: PR Newswire
Date: April, 24 2018 06:50
Premarket analyst action - healthcare
Synlogic (NASDAQ: SYBX ) initiated with Buy rating and $20 (104% upside) price target at H.C. Wainwright. More news on: Synlogic, Inc., Arbutus Biopharma Corp, Ignyta, Inc., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 19 2018 08:47
Your Daily Pharma Scoop: Portola Update, Wave Life Sciences To Collaborate With Takeda, AbbVie Reports Data For Egolix
Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will discuss Portola Pharmaceuticals ( PTLA ), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. Portola reported that the European Medicines Agency’s ((EM...
Source: SeekingAlpha
Date: February, 21 2018 11:49
Evofem Bio's Amphora Fast Track'd for prevention of chlamydia in women
The FDA has designated Evofem Biosciences' (NASDAQ: EVFM ) Amphora (L-lactic acid, citric acid and potassium bitartrate) vaginal gel for Fast Track review for the prevention of urogenital chlamydia in women. More news on: Evofem Biosciences, Inc., Healthcare stocks news, Stocks on the mo...
Source: SeekingAlpha
Date: February, 21 2018 08:44
Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia
SAN DIEGO , Feb. 21, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Source: PR Newswire
Date: February, 21 2018 06:55
Evofem Biosciences to Present at RBC Global Healthcare Conference
SAN DIEGO , Feb. 16, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that Saundra Pelletier , CEO, will present at the 2018 RBC C...
Source: PR Newswire
Date: February, 16 2018 06:55
Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule
SAN DIEGO , Feb. 15, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, announced early completion of enrollment in its Phase 3 clinical trial evalua...
Source: PR Newswire
Date: February, 15 2018 06:55
Your Daily Pharma Scoop: Portola Still Attractive, Johnson & Johnson Reports Q4 Results, Cerus Reports Positive Results
Analysis of top Seeking Alpha coverage: Portola Today we will focus on Portola Pharmaceuticals ( PTLA ), which had an excellent 2017. PTLA has made a decent start to 2018 as well, gaining more than 4%. Earlier this week, PTLA announced an abstract providing interim results from its ong...
Source: SeekingAlpha
Date: January, 25 2018 08:00
Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019
SAN DIEGO , Jan. 23, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage specialty biopharmaceutical company focused on the development and commercialization of women's healthcare products, today announced enrollment of the first patient in a Phase 2b /3 ...
Source: PR Newswire
Date: January, 23 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-175.285.235.445.0122,851

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-171,84010,30017.8641Cover
2018-08-1618,80123,59679.6788Short
2018-08-1514,81226,30856.3023Short
2018-08-1417,94862,47928.7265Cover
2018-08-1314,80346,59331.7709Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EVFM.


About Evofem Biosciences, Inc. (NASDAQ: EVFM)

Logo for Evofem Biosciences, Inc. (NASDAQ: EVFM)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $13,088,764 - 05/15/2018
    • Issue and Outstanding: 2,308,424 - 01/18/2018

     


    Recent Filings from (NASDAQ: EVFM)

    Withdrawal of registration statement filed under the Securities Act
    Filing Type: RWFiling Source: edgar
    Filing Date: May, 16 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 16 2018
    General form for registration of securities under the Securities Act of 1933
    Filing Type: S-1Filing Source: edgar
    Filing Date: May, 16 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 14 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 09 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 08 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: May, 01 2018
    Amendment to general form for registration of securities under the Securities Act of 1933
    Filing Type: S-1/AFiling Source: edgar
    Filing Date: April, 24 2018
    Amendment to a previously filed 8-K
    Filing Type: 8-K/AFiling Source: edgar
    Filing Date: April, 06 2018

     

     


    Daily Technical Chart for (NASDAQ: EVFM)

    Daily Technical Chart for (NASDAQ: EVFM)


    Stay tuned for daily updates and more on (NASDAQ: EVFM)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: EVFM)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EVFM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EVFM and does not buy, sell, or trade any shares of EVFM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/